IL6 and COVID-19: For severe COVID-19 condition, anti-inflammatory intervention such as corticosteroids (dexamethasone) (16), interleukin-6 (IL-6) receptor blockers (tocilizumab) (17), and baricitinib (18), a Janus kinase inhibitor, have shown to result in clinical improvement and reduce mortality.